BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026
February 22, 2024 01:31 ET
|
BioPorto A/S
February 22, 2024 Announcement no. 03 BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 COPENHAGEN, DENMARK and BOSTON, MA, February 22,...
Roche Diagnostics and BioPorto expand collaboration
February 20, 2024 02:28 ET
|
BioPorto A/S
20 February 20, 2024Announcement no. 02 Roche Diagnostics and BioPorto expand collaboration COPENHAGEN, DENMARK and BOSTON, MA, 20 February, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the...
BioPorto A/S to host investor meetings on 22 February 2024
February 19, 2024 01:41 ET
|
BioPorto A/S
19 February 2024News Release BioPorto A/S to host investor meetings on 22 February 2024 COPENHAGEN, DENMARK and BOSTON, Mass., 19 February 2024, BioPorto A/S (BioPorto or Company), an...
BioPorto implements changes to the Executive Management.
January 09, 2024 13:42 ET
|
BioPorto A/S
January 9, 2024 Announcement no. 01 BioPorto implements changes to the Executive Management. COPENHAGEN, DENMARK and BOSTON, MA, January 9, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the...
Managers’ transactions
December 09, 2023 12:12 ET
|
BioPorto A/S
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company)...
FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI)
December 08, 2023 11:02 ET
|
BioPorto A/S
8 December 2023 News Release FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI) One in four children can develop life-threatening kidney...
BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år
December 08, 2023 02:13 ET
|
BioPorto A/S
8. december 2023 Pressemeddelelse BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år BioPorto A/S...
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
December 07, 2023 16:22 ET
|
BioPorto A/S
December 7, 2023 Announcement no. 20 BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United StatesFirst Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years ...
Resignation of Director
December 04, 2023 14:00 ET
|
BioPorto A/S
December 4, 2023Announcement no. 19 Resignation of Director COPENHAGEN, DENMARK and BOSTON, MA, USA, December 4, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR)...
BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference
November 01, 2023 12:40 ET
|
BioPorto A/S
November 1, 2023 News Release BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023,...